Skip to main content

Table 1 Baseline characteristics of early infliximab induction and delayed infliximab induction groups at infliximab initiation

From: Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study

Characteristics Early infliximab induction (n = 73) Delayed infliximab induction (n = 44) p value
Sex (male), n (%) 56 (76.7) 28 (63.6) 0.128
Age at inclusion, years (IQR) 25.0 (20.0–29.0) 24.0(21.0–31.75) 0.547
BMI, kg/m2 (mean ± SD) 18.98 ± 2.77 19.12 ± 2.91 0.810
Mean disease duration, months (IQR)
 Luminal disease 9.0 (1.0–39.0) 4.5 (1.0–24.0) 0.294
 Perianal disease 12.0 (3.0–35.0) 19.0 (5.25–30.5) 0.354
Smoking status, n (%)    0.511
 Non-smokers 69 (94.5) 39 (88.6)  
 Ex-smokers 3 (4.1) 4 (9.1)  
 Active smokers 1 (1.4) 1 (2.3)  
Initial presentation of CD, n (%)    0.029
 Perianal 40 (54.8) 33 (75.0)  
 Luminal 33 (45.2) 11 (25.0)  
Types of fistula, n (%)    0.614
 Anorectal 68 (93.2) 39 (88.6)  
 Invade to adjacent organa 5 (6.8) 5 (11.4)  
Complex fistulas (AGA), n (%) 66 (90.4) 40 (90.9) 1.000
Proctitis, n (%) 18 (24.7) 12 (27.3) 0.828
Anorectal stricture, n (%) 27 (37.0) 9 (20.5) 0.067
Presence of abscess at baseline, n (%) 42(57.5) 20(45.5) 0.205
Previous perianal surgery, n (%) 39 (53.4) 22 (50.0) 0.849
Disease behavior, n (%)    1.000
 B1-inflammation 47 (64.4) 28 (63.6)  
 B2-stricturing 25 (34.2) 16 (36.4)  
 B3-penetrating 1 (1.4) 0 (0)  
Disease location, n (%)    0.447
 L1-ileal 16 (21.9) 10 (22.7)  
 L2-colonic 10 (13.7) 3 (6.8)  
 L3-ileocolonic 40 (54.8) 29 (65.9)  
 L4-upper gastrointestinal 7 (9.6) 2 (4.6)  
Previous medical treatment, n (%)    0.753
 None 31 (42.5) 22 (50.0)  
 Infliximab 2 (2.7) 2 (4.5)  
 Immunomodulators 10 (13.7) 6 (13.6)  
 5-ASA 30 (41.1) 14 (31.8)  
  1. IQR interquartile range, SD standard deviation, BMI body mass index, CD Crohn’s disease, AGA American Gastroenterology Association, 5-ASA 5-aminosalicylic acid
  2. aVagina or urethra